Wipro, Pidilite Industries, Berger Paints, MOIL in focus
MOIL's board has approved buyback of up to 3.38 crore equity shares at Rs 205 each for an aggregate consideration not exceeding Rs 693.77 crore.
Trends on the Singapore stock exchange indicates that the Nifty could fall 51 points at the opening bell. Overseas, Asian stocks are trading mixed on Thursday after data released overnight showed U.S. consumer inflation spiked in October. Wall Street closed sharply lower on Wednesday as surging consumer prices curbed investor risk appetite and stoked worries of a protracted wave of red hot inflation. Here is the list of stocks that will be in focus for today’s session.
Wipro: The IT major announced that it is has been chosen as a strategic partner in the transformation of Aggreko’s Finance and Procurement function.
Pidilite Industries: The company reported 5.11% rise in consolidated net profit to Rs 374.65 crore on 38.8% rise in total income to Rs 2640.90 crore in Q2 FY22 over Q2 FY21.
Berger Paints India: The paint major reported a 0.95% fall in consolidated net profit to Rs 218.85 crore on a 26.75% rise in total income to Rs 2238 crore in Q2 FY22 over Q2 FY21.
Metropolis Healthcare: The pathology lab service provider reported 3.33% fall in consolidated net profit to Rs 58.27 crore on 5.75% rise in total income to Rs 308.19 crore in Q2 FY22 over Q2 FY21.
MOIL: MOIL reported 7.36% fall in consolidated net profit to Rs 51.38 crore on 4.66% fall in total income to Rs 287.04 crore in Q2 FY22 over Q2 FY21. The company’s board has approved buyback of up to 3.38 crore equity shares at Rs 205 each for an aggregate consideration not exceeding Rs 693.77 crore.
Oil India: The company reported 54.29% surge in consolidated net profit to Rs 504.46 crore on 61.34% rise in total income to Rs 3678.76 crore in Q2 FY22 over Q2 FY21.
Zomato: The food delivery giant reported a consolidated net loss of Rs 360.80 crore in Q2 FY22 as against a net loss of Rs 121.80 crore in Q2 FY21. Total income during the quarter rose 160.17% YoY to Rs 1032.10 crore.
Alembic Pharma: The United States Food and Drug Administration (USFDA) conducted an inspection at Alembic Pharmaceuticals’ Injectable Facility (F-3) located at Karkhadi from 28th October, 2021 to 10th November, 2021. The USFDA issued a Form 483 with 10 observations.